These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33516065)

  • 1. Honing the T cell response to HIV: Turning off the noise.
    Landau NR
    EBioMedicine; 2021 Feb; 64():103217. PubMed ID: 33516065
    [No Abstract]   [Full Text] [Related]  

  • 2. DC-based immunotherapy as strategy to purge the HIV reservoir?
    Søgaard OS
    EBioMedicine; 2019 May; 43():16-17. PubMed ID: 30981650
    [No Abstract]   [Full Text] [Related]  

  • 3. Poly(I:C) Potentiates T Cell Immunity to a Dendritic Cell Targeted HIV-Multiepitope Vaccine.
    Apostólico JS; Lunardelli VAS; Yamamoto MM; Cunha-Neto E; Boscardin SB; Rosa DS
    Front Immunol; 2019; 10():843. PubMed ID: 31105693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced induction of HIV-specific cytotoxic T lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA.
    Subramanya S; Armant M; Salkowitz JR; Nyakeriga AM; Haridas V; Hasan M; Bansal A; Goepfert PA; Wynn KK; Ladell K; Price DA; N M; Kan-Mitchell J; Shankar P
    Mol Ther; 2010 Nov; 18(11):2028-37. PubMed ID: 20648001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dancing with an escape artist.
    Deweerdt S
    Nature; 2010 Jul; 466(7304):S6-7. PubMed ID: 20631705
    [No Abstract]   [Full Text] [Related]  

  • 6. Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes.
    Garcia-Bates TM; Palma ML; Anderko RR; Hsu DC; Ananworanich J; Korber BT; Gaiha GD; Phanuphak N; Thomas R; Tovanabutra S; Walker BD; Mellors JW; Piazza PA; Kroon E; Riddler SA; Michael NL; Rinaldo CR; Mailliard RB;
    EBioMedicine; 2021 Jan; 63():103175. PubMed ID: 33450518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving defences at the portal of HIV entry: mucosal and innate immunity.
    Shattock RJ; Haynes BF; Pulendran B; Flores J; Esparza J;
    PLoS Med; 2008 Apr; 5(4):e81. PubMed ID: 18384232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can immune systems be trained to fight HIV?
    Balter M
    Science; 1999 Nov; 286(5444):1470-11. PubMed ID: 10610544
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV's ticket to ride: Cytotoxic T-lymphocyte-activated dendritic cells exploited for virus intercellular transfer.
    Zaccard CR; Watkins SC; Ayyavoo V; Rinaldo CR; Mailliard RB
    AIDS Res Hum Retroviruses; 2014 Nov; 30(11):1023-4. PubMed ID: 25354022
    [No Abstract]   [Full Text] [Related]  

  • 10. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
    Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
    EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
    Egan MA
    Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
    [No Abstract]   [Full Text] [Related]  

  • 12. Measuring HIV-1-specific T cell immunity: how valid are current assays?
    D'Souza MP; Altfeld M
    J Infect Dis; 2008 Feb; 197(3):337-9. PubMed ID: 18184092
    [No Abstract]   [Full Text] [Related]  

  • 13. Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals.
    Thiébaut R; Hejblum BP; Hocini H; Bonnabau H; Skinner J; Montes M; Lacabaratz C; Richert L; Palucka K; Banchereau J; Lévy Y
    Front Immunol; 2019; 10():874. PubMed ID: 31105698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses.
    Climent N; García I; Marradi M; Chiodo F; Miralles L; Maleno MJ; Gatell JM; García F; Penadés S; Plana M
    Nanomedicine; 2018 Feb; 14(2):339-351. PubMed ID: 29157976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of an effective CTL response against HIV and SIV infections.
    Genescà M
    J Biomed Biotechnol; 2011; 2011():103924. PubMed ID: 21976964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV vaccines: Unmasking myeloid derived suppressor cells.
    Green WR; O'Connor MA
    EBioMedicine; 2020 Nov; 61():103063. PubMed ID: 33038766
    [No Abstract]   [Full Text] [Related]  

  • 17. A therapeutic dendritic cell-based vaccine for HIV-1 infection.
    García F; Climent N; Assoumou L; Gil C; González N; Alcamí J; León A; Romeu J; Dalmau J; Martínez-Picado J; Lifson J; Autran B; Costagliola D; Clotet B; Gatell JM; Plana M; Gallart T;
    J Infect Dis; 2011 Feb; 203(4):473-8. PubMed ID: 21233310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells.
    Wee EG; Ondondo B; Berglund P; Archer J; McMichael AJ; Baltimore D; Ter Meulen JH; Hanke T
    Mol Ther; 2017 Feb; 25(2):494-503. PubMed ID: 28153096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection from HIV infection or AIDS?
    Miedema F; Meyaard L; Klein MR
    Science; 1993 Nov; 262(5136):1074-6. PubMed ID: 8235627
    [No Abstract]   [Full Text] [Related]  

  • 20. [FOXO1 transcription factor: a key player in T cell/HIV-1 interaction].
    Roux A; Bismuth G; Mangeney M
    Med Sci (Paris); 2020 Jan; 36(1):24-26. PubMed ID: 32014093
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.